DE60208397T2 - Valproinsäure zur Behandlung von Brustkrebs, Dickdarmkrebs, Kopf-Hals-Krebs, kleinzelligem Lungenkarzinom und Blutzellenkrebs in Kombination mit Bestrahlung - Google Patents
Valproinsäure zur Behandlung von Brustkrebs, Dickdarmkrebs, Kopf-Hals-Krebs, kleinzelligem Lungenkarzinom und Blutzellenkrebs in Kombination mit Bestrahlung Download PDFInfo
- Publication number
- DE60208397T2 DE60208397T2 DE60208397T DE60208397T DE60208397T2 DE 60208397 T2 DE60208397 T2 DE 60208397T2 DE 60208397 T DE60208397 T DE 60208397T DE 60208397 T DE60208397 T DE 60208397T DE 60208397 T2 DE60208397 T2 DE 60208397T2
- Authority
- DE
- Germany
- Prior art keywords
- cancer
- treatment
- use according
- valproic acid
- vpa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 54
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 50
- 201000011510 cancer Diseases 0.000 title claims abstract description 30
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 title claims description 98
- 229960000604 valproic acid Drugs 0.000 title claims description 22
- 230000005855 radiation Effects 0.000 title claims description 7
- 206010006187 Breast cancer Diseases 0.000 title claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 title claims description 5
- 208000000587 small cell lung carcinoma Diseases 0.000 title claims description 5
- 206010009944 Colon cancer Diseases 0.000 title claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 title claims description 4
- 210000000601 blood cell Anatomy 0.000 title claims description 3
- 201000010536 head and neck cancer Diseases 0.000 title description 3
- 208000014829 head and neck neoplasm Diseases 0.000 title description 3
- 102000003964 Histone deacetylase Human genes 0.000 claims abstract description 38
- 108090000353 Histone deacetylase Proteins 0.000 claims abstract description 38
- 230000000694 effects Effects 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 24
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 9
- 102000004190 Enzymes Human genes 0.000 claims abstract description 7
- 108090000790 Enzymes Proteins 0.000 claims abstract description 7
- 239000003112 inhibitor Substances 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 60
- 230000004069 differentiation Effects 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 230000001225 therapeutic effect Effects 0.000 claims description 17
- 238000002560 therapeutic procedure Methods 0.000 claims description 15
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 230000002195 synergetic effect Effects 0.000 claims description 12
- 230000000259 anti-tumor effect Effects 0.000 claims description 9
- 108010033040 Histones Proteins 0.000 claims description 7
- 241000282412 Homo Species 0.000 claims description 7
- 230000024245 cell differentiation Effects 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 230000006698 induction Effects 0.000 claims description 6
- 238000001959 radiotherapy Methods 0.000 claims description 6
- 102000006947 Histones Human genes 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 101000654471 Mus musculus NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 claims description 3
- 230000021736 acetylation Effects 0.000 claims description 3
- 238000006640 acetylation reaction Methods 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 230000009286 beneficial effect Effects 0.000 claims description 2
- 238000001794 hormone therapy Methods 0.000 claims description 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims 7
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 238000011122 anti-angiogenic therapy Methods 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000011284 combination treatment Methods 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000006882 induction of apoptosis Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 208000007660 Residual Neoplasm Diseases 0.000 abstract description 9
- 206010027476 Metastases Diseases 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000009401 metastasis Effects 0.000 abstract description 4
- 239000002253 acid Substances 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 12
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 101001095089 Homo sapiens PML-RARA-regulated adapter molecule 1 Proteins 0.000 description 12
- 102100037019 PML-RARA-regulated adapter molecule 1 Human genes 0.000 description 12
- 230000001235 sensitizing effect Effects 0.000 description 9
- 108010015181 PPAR delta Proteins 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 7
- 102000040945 Transcription factor Human genes 0.000 description 6
- 108091023040 Transcription factor Proteins 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 102000003893 Histone acetyltransferases Human genes 0.000 description 5
- 108090000246 Histone acetyltransferases Proteins 0.000 description 5
- 102100039064 Interleukin-3 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 102100020880 Kit ligand Human genes 0.000 description 5
- 101710177504 Kit ligand Proteins 0.000 description 5
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 5
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 5
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 5
- 206010043275 Teratogenicity Diseases 0.000 description 5
- 230000003556 anti-epileptic effect Effects 0.000 description 5
- 239000001961 anticonvulsive agent Substances 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 231100000211 teratogenicity Toxicity 0.000 description 5
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 102100022935 Nuclear receptor corepressor 1 Human genes 0.000 description 4
- 101710153661 Nuclear receptor corepressor 1 Proteins 0.000 description 4
- 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 4
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 229930002330 retinoic acid Natural products 0.000 description 4
- 230000005945 translocation Effects 0.000 description 4
- 206010000830 Acute leukaemia Diseases 0.000 description 3
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 3
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000009456 molecular mechanism Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 108020004017 nuclear receptors Proteins 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 102000003702 retinoic acid receptors Human genes 0.000 description 3
- 108090000064 retinoic acid receptors Proteins 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 231100000462 teratogen Toxicity 0.000 description 3
- 239000003439 teratogenic agent Substances 0.000 description 3
- 108091006107 transcriptional repressors Proteins 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 102100021455 Histone deacetylase 3 Human genes 0.000 description 2
- 101001035011 Homo sapiens Histone deacetylase 2 Proteins 0.000 description 2
- 101000899282 Homo sapiens Histone deacetylase 3 Proteins 0.000 description 2
- 101001032118 Homo sapiens Histone deacetylase 8 Proteins 0.000 description 2
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 2
- 101000857677 Homo sapiens Runt-related transcription factor 1 Proteins 0.000 description 2
- 102000026633 IL6 Human genes 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 102100025169 Max-binding protein MNT Human genes 0.000 description 2
- 108010085220 Multiprotein Complexes Proteins 0.000 description 2
- 102000007474 Multiprotein Complexes Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102000023984 PPAR alpha Human genes 0.000 description 2
- 108010037522 Promyelocytic Leukemia Protein Proteins 0.000 description 2
- 102000010876 Promyelocytic Leukemia Protein Human genes 0.000 description 2
- 102100033451 Thyroid hormone receptor beta Human genes 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 230000003081 coactivator Effects 0.000 description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 231100000378 teratogenic Toxicity 0.000 description 2
- 230000003390 teratogenic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108091008762 thyroid hormone receptors ß Proteins 0.000 description 2
- 238000011714 129 mouse Methods 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 101100123574 Arabidopsis thaliana HDA19 gene Proteins 0.000 description 1
- 101000719121 Arabidopsis thaliana Protein MEI2-like 1 Proteins 0.000 description 1
- 244000300022 Bauhinia malabarica Species 0.000 description 1
- 235000018906 Bauhinia malabarica Nutrition 0.000 description 1
- 101100042630 Caenorhabditis elegans sin-3 gene Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 1
- 101150083200 HDA1 gene Proteins 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 1
- 102100039999 Histone deacetylase 2 Human genes 0.000 description 1
- 102100021454 Histone deacetylase 4 Human genes 0.000 description 1
- 102100021453 Histone deacetylase 5 Human genes 0.000 description 1
- 102100022537 Histone deacetylase 6 Human genes 0.000 description 1
- 102100038715 Histone deacetylase 8 Human genes 0.000 description 1
- 102100038720 Histone deacetylase 9 Human genes 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 1
- 101000899259 Homo sapiens Histone deacetylase 4 Proteins 0.000 description 1
- 101000899255 Homo sapiens Histone deacetylase 5 Proteins 0.000 description 1
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 description 1
- 101001032113 Homo sapiens Histone deacetylase 7 Proteins 0.000 description 1
- 101001028019 Homo sapiens Metastasis-associated protein MTA2 Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 244000211187 Lepidium sativum Species 0.000 description 1
- 235000007849 Lepidium sativum Nutrition 0.000 description 1
- -1 Mad-1 Proteins 0.000 description 1
- 102100037511 Metastasis-associated protein MTA2 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- DTERQYGMUDWYAZ-ZETCQYMHSA-N N(6)-acetyl-L-lysine Chemical compound CC(=O)NCCCC[C@H]([NH3+])C([O-])=O DTERQYGMUDWYAZ-ZETCQYMHSA-N 0.000 description 1
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 description 1
- 108090001146 Nuclear Receptor Coactivator 1 Proteins 0.000 description 1
- 102100037223 Nuclear receptor coactivator 1 Human genes 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 208000032749 Pregnancy Diseases 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 1
- 101100297422 Schizosaccharomyces pombe (strain 972 / ATCC 24843) phd1 gene Proteins 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 102000007451 Steroid Receptors Human genes 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009125 negative feedback regulation Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000000276 neural tube Anatomy 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 102000027483 retinoid hormone receptors Human genes 0.000 description 1
- 108091008679 retinoid hormone receptors Proteins 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229940084026 sodium valproate Drugs 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01121722 | 2001-09-18 | ||
| EP01121722A EP1293205A1 (en) | 2001-09-18 | 2001-09-18 | Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease |
| PCT/EP2002/010419 WO2003024442A2 (en) | 2001-09-18 | 2002-09-17 | Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60208397D1 DE60208397D1 (de) | 2006-02-02 |
| DE60208397T2 true DE60208397T2 (de) | 2006-07-13 |
Family
ID=8178602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60208397T Expired - Lifetime DE60208397T2 (de) | 2001-09-18 | 2002-09-17 | Valproinsäure zur Behandlung von Brustkrebs, Dickdarmkrebs, Kopf-Hals-Krebs, kleinzelligem Lungenkarzinom und Blutzellenkrebs in Kombination mit Bestrahlung |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20050038113A1 (https=) |
| EP (4) | EP1293205A1 (https=) |
| JP (1) | JP2005512961A (https=) |
| AT (1) | ATE314063T1 (https=) |
| AU (1) | AU2002338716B2 (https=) |
| CA (1) | CA2460713A1 (https=) |
| CY (1) | CY1105552T1 (https=) |
| DE (1) | DE60208397T2 (https=) |
| DK (1) | DK1427403T3 (https=) |
| ES (1) | ES2252519T3 (https=) |
| WO (1) | WO2003024442A2 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7250514B1 (en) | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7381825B2 (en) * | 2003-03-17 | 2008-06-03 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| MXPA05012464A (es) * | 2003-05-21 | 2006-01-30 | Novartis Ag | Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos. |
| EP1491188A1 (en) * | 2003-06-25 | 2004-12-29 | G2M Cancer Drugs AG | Topical use of valproic acid for the prevention or treatment of skin disorders |
| CN102349927A (zh) * | 2003-08-29 | 2012-02-15 | Hdac默克研究有限责任公司 | 联合治疗癌症的方法 |
| US20050159470A1 (en) * | 2003-12-19 | 2005-07-21 | Syrrx, Inc. | Histone deacetylase inhibitors |
| US20050137234A1 (en) * | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
| US7951780B2 (en) | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
| EP1824831A2 (en) * | 2004-12-16 | 2007-08-29 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| JP5156392B2 (ja) * | 2005-02-03 | 2013-03-06 | トポターゲット ユーケー リミテッド | Ｈｄａｃ阻害剤を用いる併用療法 |
| US7869590B2 (en) * | 2005-04-12 | 2011-01-11 | Broadcom Corporation | Method and system for hardware accelerator for implementing f9 integrity algorithm in WCDMA compliant handsets |
| EP1896436A2 (en) * | 2005-05-11 | 2008-03-12 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| ATE542527T1 (de) | 2005-05-13 | 2012-02-15 | Topotarget Uk Ltd | Pharmazeutische formulierungen von hdac-hemmern |
| EA200800321A1 (ru) * | 2005-07-14 | 2008-06-30 | Такеда Сан Диего, Инк. | Ингибиторы гистондеацетилазы |
| WO2007054719A2 (en) | 2005-11-10 | 2007-05-18 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent |
| US9186339B2 (en) * | 2005-11-16 | 2015-11-17 | Universidad Nacional Autonoma De Mexico | Use of transcriptome modifying agents and chemotherapy or radiotherapy against cancer |
| RU2389484C2 (ru) * | 2005-11-18 | 2010-05-20 | Универсидад Насиональ Аутонома Де Мексико | Применение модифицирующих транскриптом агентов и химиотерапии или радиотерапии против рака |
| JP2009525955A (ja) * | 2006-01-13 | 2009-07-16 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| JP5113038B2 (ja) * | 2006-03-23 | 2013-01-09 | テムリック株式会社 | 癌治療用キットおよび癌治療用医薬組成物 |
| EP2012801A4 (en) | 2006-04-24 | 2009-08-05 | Gloucester Pharmaceuticals Inc | GEMCITABINE COMBINATION THERAPY |
| DE102006022877B4 (de) * | 2006-05-15 | 2009-01-29 | Sartorius Stedim Biotech Gmbh | Verfahren zur Bestimmung der Viabilität von Zellen in Zellkulturen |
| US8957027B2 (en) | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
| EP2056808A4 (en) * | 2006-08-28 | 2009-12-23 | Univ California | Small molecule potentiator of hormonal therapy for breast cancer |
| CA2671649A1 (en) * | 2006-12-06 | 2008-06-12 | Sapporo Medical University | Potentiation of cellular immunity using histone deacetylase (hdac) inhibitors |
| GB0625283D0 (en) * | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
| AU2007342028B2 (en) | 2006-12-29 | 2013-06-13 | Celgene Corporation | Purifiction of romidepsin |
| GB2454118B (en) * | 2007-06-06 | 2010-06-02 | Univ Maryland | Hdac inhibitors and hormone targeted drugs for the treatment of cancer |
| US8642809B2 (en) | 2007-09-25 | 2014-02-04 | Topotarget Uk Ltd. | Methods of synthesis of certain hydroxamic acid compounds |
| WO2010064422A1 (ja) * | 2008-12-02 | 2010-06-10 | 静岡県公立大学法人 | ヒストン高アセチル化状態における光増感処理による腫瘍殺傷法 |
| US8491927B2 (en) | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
| NZ605526A (en) | 2010-07-12 | 2015-04-24 | Celgene Corp | Romidepsin solid forms and uses thereof |
| US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
| KR101733189B1 (ko) * | 2010-10-06 | 2017-05-08 | (주)아모레퍼시픽 | 손톱 또는 발톱 성장 촉진용 조성물 |
| CA2829263C (en) * | 2011-03-21 | 2020-05-12 | Valcuria Ab | A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof. |
| AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
| AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
| NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
| JP6551963B2 (ja) * | 2014-05-14 | 2019-07-31 | 国立大学法人京都大学 | 巨核球前駆細胞の製造方法 |
| MX388409B (es) | 2014-06-12 | 2025-03-19 | Cedars Sinai Medical Center | Composiciones y metodos para tratar canceres. |
| GB202102606D0 (en) * | 2021-02-24 | 2021-04-07 | Univ Oxford Innovation Ltd | Treatment of ovarian cancer minimal residual disease |
| CN117693363A (zh) * | 2021-07-27 | 2024-03-12 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935450A (en) * | 1982-09-17 | 1990-06-19 | Therapeutical Systems Corporation | Cancer therapy system for effecting oncolysis of malignant neoplasms |
| CA1339034C (en) * | 1988-08-22 | 1997-04-01 | Paul A. Tremblay | Platinum complexes of single isomer neoalkyl acids |
| JPH0279969A (ja) * | 1988-09-19 | 1990-03-20 | Shigeyoshi Fujimoto | 細胞障害性ｔ細胞誘導及び活性化の方法 |
| FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| EP0632008B1 (en) * | 1993-06-01 | 1998-02-04 | Ono Pharmaceutical Co., Ltd. | Pentanoic acid derivatives |
| US5672746A (en) * | 1994-08-30 | 1997-09-30 | American Biogenetic Sciences, Inc. | Antiproliferative and neurotrophic molecules |
| US6300373B1 (en) * | 1993-09-10 | 2001-10-09 | American Biogenetic Sciences, Inc. | Antiproliferative and neurotrophic molecules |
| US5786344A (en) * | 1994-07-05 | 1998-07-28 | Arch Development Corporation | Camptothecin drug combinations and methods with reduced side effects |
| ATE229810T1 (de) * | 1996-10-11 | 2003-01-15 | Univ California | Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen |
| US6110955A (en) * | 1997-03-11 | 2000-08-29 | Beacon Laboratories, Inc. | Metabolically stabilized oxyalkylene esters and uses thereof |
| US6110970A (en) * | 1997-03-11 | 2000-08-29 | Beacon Laboratories, Inc. | Nitrogen-containing oxyalkylene esters and uses thereof |
| US6124495A (en) * | 1997-03-11 | 2000-09-26 | Beacon Laboratories, Inc. | Unsaturated oxyalkylene esters and uses thereof |
| US6043389A (en) * | 1997-03-11 | 2000-03-28 | Mor Research Applications, Ltd. | Hydroxy and ether-containing oxyalkylene esters and uses thereof |
| US5939455A (en) * | 1997-03-11 | 1999-08-17 | Beacon Laboratories, Inc. | Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives |
| US6028102A (en) * | 1998-02-24 | 2000-02-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Anticonvulsant drugs and pharmaceutical compositions thereof |
| AU2337601A (en) * | 1999-12-23 | 2001-07-09 | Ontario Cancer Institute, The | Inhibition of gsk-3beta |
| EP1170008A1 (en) * | 2000-07-07 | 2002-01-09 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Valproic acid and derivatives thereof as histone deacetylase inhibitors |
-
2001
- 2001-09-18 EP EP01121722A patent/EP1293205A1/en not_active Withdrawn
-
2002
- 2002-09-17 DE DE60208397T patent/DE60208397T2/de not_active Expired - Lifetime
- 2002-09-17 ES ES02777129T patent/ES2252519T3/es not_active Expired - Lifetime
- 2002-09-17 EP EP02777129A patent/EP1427403B8/en not_active Expired - Lifetime
- 2002-09-17 AU AU2002338716A patent/AU2002338716B2/en not_active Ceased
- 2002-09-17 CA CA002460713A patent/CA2460713A1/en not_active Abandoned
- 2002-09-17 US US10/489,770 patent/US20050038113A1/en not_active Abandoned
- 2002-09-17 WO PCT/EP2002/010419 patent/WO2003024442A2/en not_active Ceased
- 2002-09-17 AT AT02777129T patent/ATE314063T1/de active
- 2002-09-17 DK DK02777129T patent/DK1427403T3/da active
- 2002-09-17 EP EP05101081A patent/EP1529527A3/en not_active Withdrawn
- 2002-09-17 JP JP2003528538A patent/JP2005512961A/ja active Pending
- 2002-09-17 EP EP05019659A patent/EP1602371A3/en not_active Withdrawn
-
2006
- 2006-02-28 CY CY20061100277T patent/CY1105552T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003024442A2 (en) | 2003-03-27 |
| EP1602371A2 (en) | 2005-12-07 |
| DK1427403T3 (da) | 2006-04-03 |
| WO2003024442A3 (en) | 2003-09-18 |
| EP1602371A3 (en) | 2006-11-15 |
| EP1427403B1 (en) | 2005-12-28 |
| CY1105552T1 (el) | 2010-07-28 |
| AU2002338716B2 (en) | 2007-08-16 |
| DE60208397D1 (de) | 2006-02-02 |
| ATE314063T1 (de) | 2006-01-15 |
| EP1427403A2 (en) | 2004-06-16 |
| EP1293205A1 (en) | 2003-03-19 |
| JP2005512961A (ja) | 2005-05-12 |
| ES2252519T3 (es) | 2006-05-16 |
| CA2460713A1 (en) | 2003-03-27 |
| EP1529527A3 (en) | 2005-05-25 |
| EP1427403B8 (en) | 2006-03-22 |
| EP1529527A2 (en) | 2005-05-11 |
| US20050038113A1 (en) | 2005-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60208397T2 (de) | Valproinsäure zur Behandlung von Brustkrebs, Dickdarmkrebs, Kopf-Hals-Krebs, kleinzelligem Lungenkarzinom und Blutzellenkrebs in Kombination mit Bestrahlung | |
| DE60110912T2 (de) | Valproinsäure und deren derivate als histondeacetylaseinhibitoren | |
| DE69435086T2 (de) | Phenylacetate und Derivate, allein oder in Kombination mit anderen Verbindungen, zur Behandlung von neoplastischen und anderen Erkrankungen | |
| DE69230131T2 (de) | Apoptoseregulator | |
| DE69328910T2 (de) | Verwendung von 9-cis-Retinsäure sowie ihre Salze und Ester, zur Behandlung von Epitheltumore | |
| DE69634532T2 (de) | Verwendung von Retinsäure-Rezeptor-Agonisten oder AP-1-Antagonisten zur Herstellung eines Medikaments zur Prävention der Proliferation des retinalen Pigmentepithels | |
| DE69711894T2 (de) | Lipoxinverbindungen und deren verwendung zur behandlung der zellenwucherungsstörung | |
| JP4965764B2 (ja) | 過増殖性障害の治療 | |
| Birnbaum et al. | Retinoic acid and 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin selectively enhance teratogenesis in C57BL/6N mice | |
| DE69832712T2 (de) | Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen | |
| AU2002338716A1 (en) | Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease | |
| DE69131386T2 (de) | Verwendung von L-Deprenyl zur Hemmung des Alterniedergangs des Immunsystems in Säugetieren | |
| DE60121145T2 (de) | Behandlung von tumoren mit rar alpha selektiven retinoid-verbindungen zusammen mitanderen antitumormitteln | |
| DE69720745T2 (de) | Therapeutische kombinationen von rar-antagonisten und rxr-agonisten | |
| DE60214846T2 (de) | Verwendung von mGLuR5 antagonists zur Herstellung von Medikamenten zur Behandlung von empfindlichen X Syndrome, Autismus und geistiger Zurückgebliebenheit | |
| DE69027991T2 (de) | Therapeutische anwendung einer antiinvasiven verbindung | |
| DE69029654T2 (de) | Verwendung von lipoxin a 4? und dessen derivaten als antagonisten für trägreagierende anaphylaxmittel | |
| Liu et al. | Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARα/γ ligand TZD18 | |
| DE69121706T2 (de) | O6-benzylierte guanine, guanosine und 2'-deoxyguanosine verbindungen mit o6-alkylguanin-dna-alkyltransferase dezimierter aktivitaet | |
| DE69012620T2 (de) | Unterdrückung der Synthese und der Sekretion des Nebenschilddrüsenhormons mit Vitamin D3-Derivaten. | |
| DE3100191C2 (https=) | ||
| EP0769296B1 (de) | Verwendung eines Natrium- oder Lysiniumsalzes von Crotonsäureamidderivaten zur Herstellung eines Arzneimittels zur Behandlung von Krebserkrankungen | |
| DE69903559T2 (de) | Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon | |
| EP0045006A1 (de) | Mittel zur Behandlung von Colitis ulcerosa, Enteritis regionalis Crohn (Morbus Crohn), chronischer unspezifischer Colitis und Divertikulitis sowie Verwendung von Salicylazobenzoesäure, zur Herstellung von derartigen Mitteln | |
| Francis et al. | Effects of dibutyryl cyclic adenosine 3′: 5′-monophosphate on the growth of cultured human small-cell lung carcinoma and the specific cellular activity of l-dopa decarboxylase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: TOPO TARGET GERMANY AG, 60596 FRANKFURT, DE |
|
| 8364 | No opposition during term of opposition |